TABLE 3.
Association between a positive amyloid PET result and clinical management parameters at follow up (n = 154)
| Variable | Follow‐up time a | Tests ordered b | DX variability b | |||
|---|---|---|---|---|---|---|
| Coef (SE) | p | Coef (SE) | p | Coef (SE) | p | |
| Intercept | 6.71 (7.79) | 0.39 | −1.03 (1.99) | 0.60 | −2.67 (1.05) | 0.01 |
| Amyloid PET result* | 4.41 (1.20) | <0.001 | −2.58 (0.73) | <0.001 | −1.37 (0.20) | <0.001 |
| Age | 0.04 (0.10) | 0.96 | −0.04 (0.03) | 0.09 | 0.01 (0.14) | 0.43 |
| MoCA | −0.01 (0.13) | 0.67 | 0.05 (0.04) | 0.27 | −0.001(0.02) | 0.97 |
| Cognitive syndrome ** | −1.49 (1.34) | 0.27 | 0.37 (0.40) | 0.36 | −0.05 (0.19) | 0.98 |
| Clinical diagnosis *** | 2.09 (1.21) | 0.09 | −0.86 (0.34) | 0.01 | −0.07 (0.17) | 0.67 |
| Variable | ChEI prescriptions c | Social work referrals b | Research trials referrals b | |||
|---|---|---|---|---|---|---|
| Coef (SE) | p | Coef (SE) | p | Coef (SE) | p | |
| Intercept | 0.03 (0.08) | 0.19 | −8.79 (2.53) | 0.001 | −6.13 (2.20) | 0.005 |
| Amyloid PET result* | 6.29 (2.94) | <0.001 | 0.40 (0.37) | 0.28 | 3.00 (0.73) | <0.001 |
| Age | 1.06 (0.04) | 0.12 | 0.07 (0.03) | 0.04 | −0.02 (0.03) | 0.55 |
| MoCA | 0.94 (0.04) | 0.19 | −0.05 (0.04) | 0.26 | 0.04 (0.05) | 0.44 |
| Cognitive syndrome ** | 2.65 (1.24) | 0.04 | 0.97 (0.43) | 0.03 | −0.09 (0.41) | 0.83 |
| Clinical diagnosis *** | 0.71 (0.31) | 0.43 | 0.25 (0.42) | 0.001 | 0.42 (0.48) | 0.38 |
Abbreviations: DX: diagnosis, ChEI: cholinesterase inhibitors, Coef: coefficient, SE: standard error, MoCA: Montreal Cognitive Assessment
a
linear regression.
b
Poisson regression adjusted for difference in follow‐up time.
c
logistic regression.
* Referent: positive versus negative, ** Referent: Dementia versus mild cognitive impairment, *** Referent: Alzheimer's disease (AD) versus Non‐AD